scholarly journals Recurrent Ovarian Cancer — Basic Knowledge, Current Management, and Future Directions

10.5772/60609 ◽  
2016 ◽  
Author(s):  
Bernardo L. Rapoport
Keyword(s):  
Ovarian Cancer ◽  
Recurrent Ovarian Cancer ◽  
Basic Knowledge ◽  
Current Management ◽  
Future Directions

Ovarian cancer: current management and future directions

2018 ◽  
Vol 28 (6) ◽  
pp. 171-176 ◽  
Author(s):  
Purushothaman Natarajan ◽  
Sian E. Taylor ◽  
John M. Kirwan
Keyword(s):  
Ovarian Cancer ◽  
Current Management ◽  
Future Directions

scholarly journals The Protein Landscape of Mucinous Ovarian Cancer: Towards a Theranostic

Cancers ◽  
2021 ◽  
Vol 13 (22) ◽  
pp. 5596
Author(s):  
Arkan Youssef ◽  
Mohammad B. Haskali ◽  
Kylie L. Gorringe
Keyword(s):  
Ovarian Cancer ◽  
Personalised Medicine ◽  
Membrane Expression ◽  
Management Options ◽  
Current Management ◽  
Future Directions ◽  
Disease Outcomes ◽  
Theranostic Agents ◽  
Selection Of ◽  
Target Effects

MOC is a rare histotype of epithelial ovarian cancer, and current management options are inadequate for the treatment of late stage or recurrent disease. A shift towards personalised medicines in ovarian cancer is being observed, with trials targeting specific molecular pathways, however, MOC lags due to its rarity. Theranostics is a rapidly evolving category of personalised medicine, encompassing both a diagnostic and therapeutic approach by recognising targets that are expressed highly in tumour tissue in order to deliver a therapeutic payload. The present review evaluates the protein landscape of MOC in recent immunohistochemical- and proteomic-based research, aiming to identify potential candidates for theranostic application. Fourteen proteins were selected based on cell membrane localisation: HER2, EGFR, FOLR1, RAC1, GPR158, CEACAM6, MUC16, PD-L1, NHE1, CEACAM5, MUC1, ACE2, GP2, and PTPRH. Optimal proteins to target using theranostic agents must exhibit high membrane expression on cancerous tissue with low expression on healthy tissue to afford improved disease outcomes with minimal off-target effects and toxicities. We provide guidelines to consider in the selection of a theranostic target for MOC and suggest future directions in evaluating the results of this review.

Ovarian cancer: current management and future directions

2015 ◽  
Vol 25 (2) ◽  
pp. 37-42
Author(s):  
Antonios Anagnostopoulos ◽  
Sian E. Taylor ◽  
John M. Kirwan
Keyword(s):  
Ovarian Cancer ◽  
Current Management ◽  
Future Directions

Resource Utilization and Expenditures During the “Watchful Waiting” Period in Patients With Recurrent Ovarian Cancer

2019 ◽  
Vol 5 (1) ◽  
pp. 40-48 ◽  
Author(s):  
Brooke Harrow ◽  
Karin Travers ◽  
Brian M Davis ◽  
Paula Smith ◽  
Adrienne M Gilligan ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Resource Utilization ◽  
Watchful Waiting ◽  
Recurrent Ovarian Cancer ◽  
Waiting Period
Sign in / Sign up

Export Citation Format

Share Document